ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been ... The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has completed a phase 1 study, and Novo Nordisk ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Mar. 17, 2025 — The James Webb Space Telescope has captured its first direct images of carbon dioxide in a planet outside the solar system in HR 8799, a multiplanet system 130 light-years away ...

After hours: March 21 at 7:59:39 PM EDT ...